Apr 18,2018

Feel Therapeutics Closes Seed Round to Change the Way We Manage Mental Health

Feel Therapeutics, Inc., a developer of artificial emotional intelligence technology that changes the way we monitor and manage mental health, today announced that it has raised a total of $1.8 million in seed funding from Anthemis Exponential Ventures, SOSV, Make in LA and angel investors.

FUNDING SEED ROUND
View Analyst & Ambassador Comments
Go to original news
Aug 11,2023

Nemaura Medical Secures $6.5m in Non-Dilutive Funding

Nemaura Medical, a medical technology company focused on commercializing a daily disposable wearable glucose sensor and supporting personalized digital coaching programs, announces today that it has secured a further $6.5 million in non-dilutive funding though a clean debt facility with no warrants or convertible elements, from its existing lender. The company is also currently undertaking studies with the NHS (National Health Service) in the UK with its metabolic health program designed for the consumer market targeting obesity and pre-diabetes whilst refining its commercial offering in this space. Nemaura also continues to support its UK licensee with its application for reimbursement of sugarBEAT® in the UK.

FUNDING DEBT FINANCE
View Analyst & Ambassador Comments
Go to original news
Feb 01,2017

Lark Health Raises $20M in Series B

Lark Health, a provider of chronic disease prevention and management programs, closed a $55 million Series C funding round as well as a $15 million venture debt credit facility. The company’s Series A funding round in 2013 raised about $11 million, and its Series B funding round raised approximately $20 million in 2017, Lark Health CEO Julia Hu said.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
May 25,2023

HelloBetter continues successful path with Heuking – another seven million euros raised for U.S. expansion

A team led by Salaried Partner Christoph Prochnau from Heuking’s Hamburg office again advised HelloBetter on the expansion of its Series A funding round. MassMutual Ventures (MMV), HealthCap, Sparrow Ventures, Hevella Capital, and Expon Capital invested another EUR 7 million in the Hamburg-based startup. With this expansion, the volume of the Series A funding round – despite the challenging market environment for venture capital financing – has now increased to a total of EUR 20 million.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
May 25,2023

HelloBetter continues successful path with Heuking – another seven million euros raised for U.S. expansion

A team led by Salaried Partner Christoph Prochnau from Heuking’s Hamburg office again advised HelloBetter on the expansion of its Series A funding round. MassMutual Ventures (MMV), HealthCap, Sparrow Ventures, Hevella Capital, and Expon Capital invested another EUR 7 million in the Hamburg-based startup. With this expansion, the volume of the Series A funding round – despite the challenging market environment for venture capital financing – has now increased to a total of EUR 20 million

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Jul 25,2023

Better Therapeutics Announces $6.7 Million in New Financing at an Average Price of $0.77 per Share

Better Therapeutics raised $6.7 million through equity offerings to support the launch of AspyreRx™, a prescription-only digital therapy for adults with type 2 diabetes, as a result of the issuance of 2,023,583 shares of its common stock under its At-The-Market program at an average price per share of $1.19.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Jul 25,2023

Better Therapeutics Announces $6.7 Million in New Financing at an Average Price of $0.77 per Share

Better Therapeutics raised $6.7 million through equity offerings to support the launch of AspyreRx™, a prescription-only digital therapy for adults with type 2 diabetes, as a result of the issuance of 2,023,583 shares of its common stock under its At-The-Market program at an average price per share of $1.19.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Jul 23,2018

Alex Therapeutics receives funding from the King founders

Last year the billionaire entrepreneurs behind King.com founded the venture fund Sweet Studio. The fund, which manages roughly 100 million SEK in capital, has now made its first investment in Alex Therapeutics. After the massively successful video game developer King.com was purchased for over 50 billion SEK by Activision Blizzard, the founders have now invested part of their fortune in twenty new tech companies through the venture fund Sweet Capital. Through the investment Anders Frostenson also joins the board of Alex Therapeutics.

FUNDING VENTURE ROUND
View Analyst & Ambassador Comments
Go to original news
Jun 15,2023

Wellthy Therapeutics adds Beyond Next Ventures as an investor; Expands into Japan

Wellthy Therapeutics is proud to announce that it has secured additional financing, led by Beyond Next Ventures, a venture capital firm based in Japan, with participation from existing investors. This paves the way for Wellthy Therapeutics to expand its platform into the Japanese market, enabling enterprise customers to deploy world class digital health solutions to support patients globally. "We started Wellthy Therapeutics with a vision that one day, nobody would die from preventable disease complications. We are humbled by the confidence placed in us by Beyond Next Ventures, and are excited by the opportunity to further accelerate our vision of impacting 10 million patients in this decade, by helping Japanese life science and healthcare enterprise customers achieve better real-world outcomes," said Abhishek Shah, CEO of Wellthy Therapeutics.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Jun 15,2023

IMAGIO consortium receives Innovative Health Initiative EUR 24 million grant to improve cancer treatments

Royal Philips today announced that the Philips-coordinated IMAGIO consortium of clinical partners has been awarded a EUR 24 million Innovative Health Initiative (IHI) grant, complemented with additional resources and funding from industry partners, to carry out research into less invasive cancer treatments. Consisting of approximately 30 partners, the consortium will use the funding to improve clinical outcomes with interventional oncology innovations focused on lung cancer, liver cancer and soft tissue sarcomas. Leading European hospitals participating in the consortium include Leiden, Maastricht, Radboud and Utrecht University Medical Centers in the Netherlands and University Hospital of Cologne in Germany.

FUNDING GRANT
View Analyst & Ambassador Comments
Go to original news
Subscribe to FUNDING